Navigation Links
Laureate Biopharma to Produce Biosimilar Product for Leading Generics Company
Date:7/25/2011

PRINCETON, N.J., July 25, 2011 /PRNewswire/ -- Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced that they have entered into a multi-year development and manufacturing agreement with a leading generic pharmaceutical company to produce a biosimilar product.  Laureate's services will include transfer of the manufacturing process to Laureate and cGMP manufacture of this product for clinical trials through 2013. The agreement includes a customer option for long-term commercial supply.  Laureate expects to supply the first batch of clinical product during the first half of 2012.  Terms of the manufacturing agreement were not disclosed.

"Biosimilars are the immediate growth engine of the generic industry and we are pleased to be working with one of the leading generic companies in the world on this product," said Michael A. Griffith, CEO of Laureate Biopharma. "Manufacture of biosimilars is one natural extension of Laureate's existing portfolio of contract manufacturing services and represents a key strategic step for the company."  

About Biosimilars

Biosimilars are subsequent versions of recombinant therapeutic innovator products manufactured and sold by a different corporate sponsor following expiry of patent exclusivity for the innovator product.  With many innovator biopharmaceutical products going off patent in the next 5-10 years, there is an industry-wide effort to develop corresponding biosimilars. The U.S. FDA was given the authority to approve biosimilars within the Patient Protection and Affordable Care Act of 2010, following similar approvals in the European Union.  

About Laureate Biopharmaceutical Services, Inc.

Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC.  For more information, please visit www.LBioS.com.

About Saints Capital, LLC

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit www.saintsvc.com.

For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Biopharma, at (609) 919-3367, or info@LBioS.com or visit www.LBioS.com.


'/>"/>
SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Laureates Electronic Submission Gateway Approved
2. Laureate Pharma Changes Name to Laureate Biopharmaceutical Services, Inc.
3. Laureate Pharma Launches New Regulatory Affairs Services and Appoints Robert G. Burford, Ph.D., as Vice President
4. Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals Antibody Therapeutic
5. Elsevier Celebrates Nine 2010 Nobel Laureates and Honors Achievements With Freely Available Prize-Winning Research
6. Laureate Pharma Secures $20 Million to Enhance and Grow Biopharmaceutical Contract Manufacturing Business
7. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development
8. Thomson Reuters Predicts Nobel Laureates
9. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
10. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
11. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , 22. März 2017   ... und weltweit tätige Anbieter von Produkten und ... den Erwerb von EPL Archives Inc. bekannt, ... der Kunden im kompletten Zyklus regulierter Forschung, ... von Proben, Speicherung von Dokumenten und Zusatzdienstleistungen ...
(Date:3/22/2017)... 2017 TapImmune, Inc. (NASDAQ: ... development of innovative peptide and gene-based immunotherapeutics for ... announced that it will participate in two upcoming ... Glynn Wilson , Chairman and CEO of TapImmune, ... clinical pipeline and partnering opportunities for its proprietary ...
(Date:3/22/2017)... 22, 2017 A new independent study ... the proven ultraviolet-C (UV-C) disinfection solution of choice ... Published in the March issue ... , the peer-reviewed study of UV-C disinfection systems ... General Hospital and Rochester General Hospital. According to ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Donor ... and Nevada and LABS, Inc., announced the future opening of a CLIA certified ... and serology testing used to determine the suitability of potential organ and ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... solution provider, today announced that its digital marketing solutions have enabled Children’s Hospital ... investment in 24 months. , Recognizing the value of a digital marketing ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, ... to accept new patients in need of skilled pediatric dentistry in Rock ... Care offers pediatric patients routine treatments, including cavities, sealants and fluoride applications, in a ...
(Date:3/22/2017)... Milford, PA (PRWEB) , ... March 22, 2017 , ... ... producers, according to a US Department of Agriculture report. While excess dairy can ... sensitivity play a role. Lactose sensitivity is the inability to properly digest lactose, a ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... financial consultations to families and business owners in the greater Hampton Roads area, ... American Cancer Society Relay For Life event. , Each year, hundreds of people ...
Breaking Medicine News(10 mins):